FRONTIER1: a partially randomized phase 2 study assessing the safety, PK, and PD of Mim8, a factor VIIIa mimetic

CONCLUSIONS: These data support the continued clinical development of Mim8, and FRONTIER1 has proceeded onto an extension phase.PMID:38142846 | DOI:10.1016/j.jtha.2023.12.016

Source: Thrombosis and Haemostasis - December 24, 2023 Category: Hematology Authors: Steven R Lentz Pratima Chowdary Lidia Gil Francisco J Lopez-Jaime Johnny Mahlangu Irina Matytsina Anne Louise Nielsen Jerzy Windyga Source Type: research